STOCK TITAN

Spectral AI, Inc. Warrants - MDAIW STOCK NEWS

Welcome to our dedicated page for Spectral AI Warrants news (Ticker: MDAIW), a resource for investors and traders seeking the latest updates and insights on Spectral AI Warrants stock.

Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.

Latest News: DALLAS, April 30, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the company received the Commitment to Quality Achievement Award from the Texas Manufacturer Assistance Center (TMAC) for their UKCA Mark Attainment. “Spectral AI is honored to be recognized as an upcoming leader in the Texas Manufacturing space,” said Louis Percoco, Spectral AI’s General Manager. “Our mission is to bring innovation and solutions to wound care through the company’s DeepView™ technology with the utmost quality and a strong manufacturing backbone is vital as we continue driving towards commercialization of the product. We are proud to be part of the local business infrastructure and appreciate the support and recognition for the focus the team brought to the table by the Texas manufacturing community.” TMAC, which is associated with the Manufacturing Extension Partnership (MEP) of the National Institute of Standards and Technology (NIST) aims for Texas manufacturers to achieve profitable growth and increased competitiveness. The non-profit program supports Texas manufacturers by granting business management consulting services, new technologies implementation, operations streamlining, workforce development, and strategic planning. Their services extend beyond manufacturers and also include distribution, logistics, construction, healthcare, and government entities. This award heralds in a new era of quality excellence and leadership for Spectral AI as they move toward product commercialization.

Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) announced a Letter to Shareholders detailing the Company's progress towards commercializing its AI-driven DeepView System for wound assessment and treatment. The letter highlights a $149 million contract from BARDA, revenue generation expectations, FDA and UKCA marking for proprietary technology, promising interim results for DFU Clinical Study, and new management appointments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
AI
-
Rhea-AI Summary
Spectral MD, Inc. announces the submission of an application in the UK for its predictive software DeepView AI®-Burn to be registered as UK Conformity Assessed for burn wound use. This marks a significant step towards commercialization for the company's AI software in the medical diagnostics field, specifically for thermal burn wounds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
none
-
Rhea-AI Summary
Spectral AI, Inc. (MDAI) announces the enrollment of the first patient in the pivotal study to validate DeepView AI® for burn size and healing assessment. The study is expected to be the final clinical trial before seeking FDA marketing authorization in 2025. The company continues to utilize $251 million of non-dilutive government funding since 2019 to validate DeepView for burn indication and other clinical indications like diabetic foot ulcers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
AI
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) has announced the hiring of Peter M. Carlson as Chief Financial Officer. Carlson brings a strong track record in senior financial executive roles at public companies, including healthcare entities, and will play a crucial role in navigating the financial landscape and strategic opportunities for Spectral AI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.23%
Tags
AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) is an AI company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care. The company announced its participation in the Benchmark 12th Annual Discovery One-on-One Conference in New York City. Spectral AI's DeepView® System has received a significant contract from the U.S. Government and has been validated through multiple clinical studies for assessing burn wounds and diabetic foot ulcers. The company expects to submit applications for FDA, UKCA, and CE mark approval for its DeepView® System in 2024 and 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.96%
Tags
conferences AI
-
Rhea-AI Summary
Spectral AI, Inc. (MDAI) appoints Erich Spangenberg as Chairman of the Executive Committee and Nominating and Corporate Governance Committee. Erich, the Company's largest shareholder, brings 40 years of experience in IP-related financings and is recognized as a top 50 IP strategist. Spectral AI received $251 million in non-dilutive funding from the US Government, and Erich aims to maximize shareholder value and reflect the intrinsic value of MDAI stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management AI
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) announced Q3 2023 financial results, affirming full-year revenue guidance for 2023 and 2024. The company highlighted progress in developing and commercializing its AI-Driven DeepView® System wound healing assessment technology. The system provides immediate wound healing potential assessment, with high accuracy for burn and diabetic foot ulcers. The company is preparing for the commercial launch of the DeepView® System as early as 2024, following regulatory approvals. Q3 2023 financial results overview showed a decline in R&D revenue, gross margin, and an increase in general & administrative expenses. The net loss was $(10.6) million, and cash and cash equivalents totaled $7.3 million as of September 30, 2023. The company reaffirmed its revenue guidance for full year 2023 and 2024, expecting 2024 revenue growth of approximately 60% from anticipated 2023 levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
-
Rhea-AI Summary
Spectral AI, Inc. will report financial results for Q3 2023 on November 13, 2023. A conference call to discuss the results will be held on November 14, 2023. Investors can access the webcast of the call on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.2%
Tags
-
Rhea-AI Summary
Spectral AI appoints Prof. Paul Chadwick as Executive VP of its UK subsidiary to expand the international market for its DeepView® wound imaging technology. Prof. Chadwick brings extensive experience in the medical devices and technology sectors, particularly in diabetic wound management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.29%
Tags
AI
Rhea-AI Summary
Spectral AI provides annual revenue guidance for 2023 and 2024 and highlights opportunities with its AI-Driven DeepView® Wound Imaging Technology. The company recently secured a contract valued at over $149.0 million from the U.S. Government.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
AI

FAQ

What is the current stock price of Spectral AI Warrants (MDAIW)?

The current stock price of Spectral AI Warrants (MDAIW) is $0.1399 as of September 13, 2024.

What is Spectral AI focused on?

Spectral AI Inc focuses on predictive medical diagnostics with its DeepView System.

What is the significance of the DeepView System?

The DeepView System distinguishes between damaged and healthy tissue for accurate healing assessments.

What recent achievement did Spectral AI have?

Spectral AI received the Commitment to Quality Achievement Award from TMAC for UKCA Mark Attainment.

Who is Louis Percoco?

Louis Percoco is Spectral AI's General Manager, leading the company towards innovation in wound care.

What does TMAC aim to achieve?

TMAC aims to help Texas manufacturers achieve growth and competitiveness through various support services.

Spectral AI, Inc. Warrants

Nasdaq:MDAIW

MDAIW Rankings

MDAIW Stock Data

17.61M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
DALLAS